stockrow
Saturday 7 November 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
- EPS
- −717.0%
- Free cash flow
- +89.0%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
2.50
0.13
−4.94%
Follow LIMN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 294.43% | 16,458.79% | 70.02% | 0.00% |
+6 more TTM periods Free account |
|
| (471.47%) | (268.39%) | (344.72%) | (337.81%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(3,447.10%) | 11,091.43% | 104.30% | 137.55% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(4.10) | (16.42) | (20.97) | (17.99) | |
Free Cash Flow |
(3.97) | (11.82) | (9.96) | (9.72) | |
| Other line items | |||||
Cash ROIC |
(83.46%) | (367.33%) | 124.01% | (1,864.37%) | |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(53.77) | (31.94) | (13.74) | (10.82) | |
Operating CF/Net income |
0.32 | 1.07 | 0.98 | 4.29 | |
Depreciation/Fixed assets |
0.19 | 0.20 | 0.15 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.10) | (16.42) | (20.97) | (17.99) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026